Publications by authors named "Albert Font"

Claim this Profile
Y
YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer.
Vicenç Ruiz de Porras, Martin K Bakht, Maria Fernandez-Saorín, Clara Alcon, Luis Palomero, Albert Font

Pharmaceuticals (Basel)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients" [Eur. Urol. Oncol. 7 (2024) 954-964].
Natalia Jiménez, Marta Garcia de Herreros, Òscar Reig, Mercedes Marín-Aguilera, Caterina Aversa, Albert Font

Eur Urol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Prognostic Expression Signature of , , and Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors" [Eur. Urol. Open Sci. 70 (2024) 86-90].
Marta Garcia de Herreros, Natalia Jiménez, Leonardo Rodríguez-Carunchio, Eva Lillo, Mercedes Marín-Aguilera, Albert Font

Eur Urol Open Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression.
Marta Garcia de Herreros, Natalia Jiménez, Joan Padrosa, Caterina Aversa, Laura Ferrer-Mileo, Albert Font

Int J Mol Sci· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.
Juan F Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández, Ricardo Collado, Ricardo Fernández, Albert Font

Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Educated Platelets in Urological Tumors: A Novel Biosource in Liquid Biopsy.
Mariona Figols, Sviatoslav Chekhun, Maria Fernández-Saorin, Ignacio Pérez-Criado, Ana Bautista, Albert Font

Int J Mol Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Expression Signature of , , and Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
Marta Garcia de Herreros, Natalia Jiménez, Leonardo Rodríguez-Carunchio, Eva Lillo, Mercedes Marín-Aguilera, Albert Font

Eur Urol Open Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease.
Judit Tomsen-Melero, Marc Moltó-Abad, Josep Merlo-Mas, Zamira V Díaz-Riascos, Edgar Cristóbal-Lecina, Albert Font

Sci Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
Natalia Jiménez, Marta Garcia de Herreros, Òscar Reig, Mercedes Marín-Aguilera, Caterina Aversa, Albert Font

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
E-learning pills on immunotherapy in urothelial carcinoma: The E-PIMUC program for continuing medical education.
Olga Romero-Clarà, Clara Madrid, Juan Carlos Pardo, Vicenç Ruiz de Porras, Olatz Etxaniz, Albert Font

Front Pharmacol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer.
Enrique Perez-Navarro, Vincenza Conteduca, Juan M Funes, Jose I Dominguez, Miguel Martin-Serrano, Albert Font

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
Albert Font, Begona Mellado, Miguel A Climent, Juan Antonio Virizuela, Stephane Oudard

Br J Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.
Vicenç Ruiz de Porras, Adrià Bernat-Peguera, Clara Alcon, Fernando Laguia, Maria Fernández-Saorin, Albert Font

Front Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury.
Vicenç Ruiz de Porras, Mariona Figols, Albert Font, Eva Pardina

Life Sci· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers.
Vicenç Ruiz de Porras, Albert Font

Int J Mol Sci· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Wassim Abida, David Campbell, Akash Patnaik, Alan H Bryce, Jeremy Shapiro, Albert Font

Eur Urol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features.
Albert Font, Montserrat Domenech, Jose Luis Ramirez, Miriam Marqués, Raquel Benítez

Front Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
Andrea Loehr, Arif Hussain, Akash Patnaik, Alan H Bryce, Daniel Castellano, Albert Font

Eur Urol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
María P Fernandez-Perez, Enrique Perez-Navarro, Teresa Alonso-Gordoa, Vicenza Conteduca, Albert Font

Prostate· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
Alejo Rodriguez-Vida, Pablo Maroto, Albert Font, Cristina Martin, Begoña Mellado

Br J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.
Miguel A Climent, Albert Font, Ignacio Durán, Javier Puente, María José Méndez-Vidal

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Albert Font, Montserrat Domenech, Oscar Buisan, Hector Lopez, Andrea González

World J Urol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions.
Vicenç Ruiz de Porras, Juan Carlos Pardo, Olatz Etxaniz, Albert Font

Crit Rev Oncol Hematol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel.
Natalia Jiménez, Òscar Reig, Mercedes Marín-Aguilera, Caterina Aversa, Laura Ferrer-Mileo, Albert Font

Cancers (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer.
Juan C Pardo, Vicenç Ruiz de Porras, Joan Gil, Albert Font, Manel Puig-Domingo

Nutrients· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis